Clinical Trials Logo
  1. Home
  2. Conjunctivitis, Allergic
  3. NCT01470118

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Conjunctivitis, Allergic Clinical Trial

Clinical Trial Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01470118
Study type Interventional
Source Allergan
Contact
Status Completed
Phase Phase 4
Start date October 2011
Completion date December 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT03709121 - A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Phase 1/Phase 2
Completed NCT02555761 - Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Completed NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Phase 4
Recruiting NCT04299399 - Corneal Biomechanical Changes of Allergic Conjunctivitis
Completed NCT00917488 - Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP). Phase 2
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A
Completed NCT02082262 - AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Phase 3
Withdrawn NCT01541904 - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Phase 2
Completed NCT00311844 - A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Phase 4
Completed NCT02161146 - AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase 3
Completed NCT00718744 - Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units Phase 2
Recruiting NCT03186755 - Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Phase 4
Completed NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea N/A
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT01289431 - Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis Phase 2
Completed NCT00655109 - A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Phase 4
Completed NCT00424398 - Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Phase 2/Phase 3
Completed NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis Phase 2